
HISTORY
2006
The start 2006
CarpoNovum is founded by two colorectal surgeons
Anders Grönberg, MD, PhD, engineer, and Prof. Henrik Thorlacius, MD, PhD
Award 2006
CarpoNovum received
Öhrlings Price Water House Coopers and LUIS Innovation awards
2007
Award 2007
CarpoNovum received the award for the most successful company in the Connect Sweden network
Award 2007
CarpoNovum received the national Skapa Development Award
2011
CE 2011
CARP®, predecessor of C-REX®, received CE marking
Developing 2011-2018
C-REX® device family was developed, clinical studies were conducted in Sweden, Denmark and China.
2018
CE 2018
CE mark is warded to the C-REX® portfolio
2020
Scandinavian CCS 2020
A subsidiary of CarpoNovum AB, is formed for surgical education and clinical practice.
ABOUT
CarpoNovum is a Swedish company innovating, manufacturing and delivering a new generation of surgical instruments for colorectal surgery.
Company’s headquarters, in-house R&D and manufacturing facilities are located in Halmstad, Sweden.
BOARD OF DIRECTORS
Otto Drakenberg
Chairman of the Board
Otto Drakenberg is a Stockholm based CEO and Board Chairman with extensive experience leading complex transformations in a range of industry sectors such as consumer goods, retail, consumer service and technology. Otto is the chairman of the board of Spendrups Brewery, Svegro and Sisjö Intressenter and was until 2022 Group CEO of Scandi Standard. His former operational roles include CEO of Carlsberg Sweden, Group CEO of the Nordic wine and liquor group Arcus, Chairman of the Board and leader of the reconstruction and sale of the retail chain Twilfit, Group CEO of Moment Group.

Lars Johansson
Member of the Board
Lars Johansson Brings 30 years of experience from the medtech and pharmaceutical industry, including 13 years as General Manager for Johnson & Johnson in the Nordics. Lars has a track record of being an extraordinary leader and his experience covers all strategic and operational aspects of bringing innovative treatments to patients.

Björn Olsen
Member of the Board
Björn Olsen Professor and Senior Consultant of Infectious Diseases since 2007 at Uppsala University and Academic Hospital. Olsen's scientific publication has (2022) according to Google Scholar over 15,000 citations and an h-index of 60. He is also an ornithologist and expert in bird-borne diseases, including bird flu. In 2010, he published the book "Pandemic". Olsen was the summer host 2006 and 2020 at one of the Swedish radio channels.

CLINICAL ADVISORY BOARD
Gunnar Németh, prof.
Clinical advisor
M.D. and professor of orthopedic surgery. Former head of the department for orthopedic surgery at Karolinska Institutet, and acting subject specialist at Region Stockholm. In 2007 he became CEO of Capio S:t Görans Hospital, and the year after that CEO of the Capio Group. Since 2011 he has been senior advisor for several companies.

Torbjörn Holm, prof.
Clinical advisor
Former surgical professor at Karolinska Institutet, specialising in colorectal surgery. He has brought significant contributions to the development of the multidisciplinary treatment of colorectal cancer in Sweden.

Roger Henriksson, prof.
Clinical advisor
Professor and senior oncologist at Norrland's University Hospital. Former leader of the regional Cancer Centrum Stockholm Gotland, and of Stockholms oncological clinic, including Radiumhemmet at Karolinska University Hospital. Furthermore, Mr. Henriksson has also been chairman of the expert panel advising Stockholm's medicinal committee.

Björn Zackrisson, Dr.
Clinical advisor
Medical specialist within general surgery and urology. Former director of Skånevård, including the hospitals of Ängelholm, Helsingborg, Landskrona and Trelleborg as well as Psychiatry Skåne. Former board member of Tiohundra AB in Norrtälje, Innovation Skåne and the Swedish Medical Association Leadership Group. He has also held leading positions at Capio, Praktikertjänst and Team Olivia.

Ulf Jungnelius, Dr.
Clinical advisor
Trained as an MD and has previously held leading roles in oncology and clinical development at the pharmaceutical companies Celgene, Takeda, Pfizer, and Eli Lilly. Jarl Jungnelius is CEO of Isofol Medical AB, and is also a member of the board of directors of CarpoNovum AB.

SURGICAL ADVISORY BOARD
Niels Qvist, prof.
Surgical advisor
Became a surgeon in 1988 and is now Head of Research at the unit for Gastroenterology Surgery at Odense University Hospital. He has published over 300 peer reviewed medical journals and holds big international network. In 2021 he obtained ethical approval for a clinical trial on the CarpoNovum C-REX in Denmark, which is currently being set up.

Torbjörn Holm, prof.
Surgical advisor
Former surgical professor at Karolinska Institutet, specialising in colorectal surgery. He has brought significant contributions to the development of the multidisciplinary treatment of colorectal cancer in Sweden.

André D'Hoore, prof.
Surgical advisor
Started as a surgeon in 1994 and is now one of Europe's leading surgeons with a big international network and post doc training at leading clinics such as Cleveland Clinic in Fort Lauderdale, St Mark's Hospital in London and the Hôpital Cantonal in Geneva. Experienced in handling new medical technologies and publishing studies. His clinical work has resulted in over 160 peer reviewed articles.

FINANCIAL ADVISORY BOARD
Johan Stein
Financial advisor
Lecturer and researcher at Stockholm School of Economics for 10 years. He gained a doctorate degree in 2011, later named docent and professor. Has been Head of research and portfolio manager at a number of hedge funds and with Nordea Investment Management. Also has experience from Alfred Berg and BNP Paribas.

Christophe Genetay
Financial advisor
M.Sc. Civ Eng. and has 25 years experience in the financial industry, working with listed and non-listed companies. Former head of training at the Swedish Council for small investors. Since 2013 been engaged with Investor Relations across various industries.

Q&R
Quality and Regulatory
C-REX® devices are CE-marked in Europe. Regulatory approval has been achieved by complying with Medical Device Directive 93/42/EC as Class IIa devices and CarpoNovum holds a certificate of current version of EN ISO 13485.
Quality policy
All team members of CarpoNovum are committed to improve lives of people undergoing colorectal surgery, by providing high-quality, safe and effective products and services that meet our customers’ needs, with focus on continual improvement, by:
-
having a close collaboration with leading surgeons and health care professionals
-
complying with all applicable regulatory requirements
-
continually improving the effectiveness of our Quality Management System
-
periodically reviewing the performance of the Quality Management System and our Quality Objectives
-
communicating this Quality Policy to all team members, subcontractors and suppliers to assure that it is understood and implemented